Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Legend Biotech CorpLEGN · Entity 4033 | Chief Financial Officer | September 21, 2026 | September 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Legend Biotech Corp
Report date September 21, 2026 · Filed September 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 14,246 |
Last balance in matching sequence
After 2026-09-21 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-09-21 · Grant · Acquired 19,676 · Balance 19,676 F1: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer. Row 2 · 2026-09-21 · Sale · Disposed 5,430 · Balance 14,246 F1: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer. F2: Represents shares sold to satisfy withholding tax obligations upon the vesting of restricted share units. F3: The price reported in Column 4 is a weighted average price. The prices sold ranged from $8.905 to $9.325 per ordinary share. The reporting person will provide the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer.
F2: Represents shares sold to satisfy withholding tax obligations upon the vesting of restricted share units.
F3: The price reported in Column 4 is a weighted average price. The prices sold ranged from $8.905 to $9.325 per ordinary share. The reporting person will provide the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 21, 2026 Filed Sep 23, 2026 20:15 UTC | Legend Biotech Corp LEGN · Entity 4033 | SaleOrdinary Shares | 5,430 | $9.14 | $49,630.20 |
DisclosureSEC source: 0002097065-26-000005 · form4-09232026_040904.xml · nonDerivative · entry 2 Santos Carlos E · CIK 0002097065 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,246 F1 · security: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer. F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the vesting of restricted share units. F3 · price: The price reported in Column 4 is a weighted average price. The prices sold ranged from $8.905 to $9.325 per ordinary share. The reporting person will provide the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 21, 2026 Filed Sep 23, 2026 20:15 UTC | Legend Biotech Corp LEGN · Entity 4033 | GrantOrdinary Shares | 19,676 | $0.00 | $0.00 |
DisclosureSEC source: 0002097065-26-000005 · form4-09232026_040904.xml · nonDerivative · entry 1 Santos Carlos E · CIK 0002097065 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,676 F1 · security: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.